Literature DB >> 8313936

Similarities between beta amyloid peptides 1-40 and 40-1: effects on aggregation, toxicity in vitro, and injection in young and aged rats.

T Giordano1, J B Pan, L M Monteggia, T F Holzman, S W Snyder, G Krafft, H Ghanbari, N W Kowall.   

Abstract

Peptides corresponding to the first 40 amino acids of beta amyloid peptide (beta 1-40) and the reverse sequence (beta 40-1) were synthesized, purified, and compared for their ability to aggregate and cause toxicity in vitro to human neuroblastoma cells (SH-SY5Y), as well as for effects following injection into young or aged rats. Aggregation of both peptides produced similar sedimentation velocity profiles and resulted in significant toxicity in vitro with no observable differences between beta 1-40 and beta 40-1. In addition, when injected into the cortex of young rats, beta 1-40 was more toxic than beta 40-1 although both resulted in significant lesions. However, in aged rats the two peptides resulted in lesions of similar size. Alz 50 staining and abnormal neurites were associated with both beta 1-40 and beta 40-1 lesions; however, no evidence of plaques or tangles was found in either age group. While both peptides were toxic in vitro, only beta 1-40 elicited Alz 50 staining of SH-SY5Y cells. Electron microscopic examination of beta 1-40 and beta 40-1 aggregates showed that beta 1-40 formed fibrillar structures whereas beta 40-1 resulted in amorphous particles. Thus, although both peptides were toxic to cultured cells and aged rats, the toxicities may have resulted from different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8313936     DOI: 10.1006/exnr.1994.1022

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  9 in total

1.  Amyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors.

Authors:  Francesca Grassi; Eleonora Palma; Raffaella Tonini; Mascia Amici; Marc Ballivet; Fabrizio Eusebi
Journal:  J Physiol       Date:  2003-01-17       Impact factor: 5.182

2.  Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes.

Authors:  Luanda Pym; Mark Kemp; Valérie Raymond-Delpech; Steven Buckingham; C A R Boyd; David Sattelle
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

3.  Beta-amyloid peptide blocks the fast-inactivating K+ current in rat hippocampal neurons.

Authors:  T A Good; D O Smith; R M Murphy
Journal:  Biophys J       Date:  1996-01       Impact factor: 4.033

4.  The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy.

Authors:  W B Stine; S W Snyder; U S Ladror; W S Wade; M F Miller; T J Perun; T F Holzman; G A Krafft
Journal:  J Protein Chem       Date:  1996-02

5.  Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain.

Authors:  W A Pedersen; M A Kloczewiak; J K Blusztajn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

6.  Substoichiometric inhibition of Abeta(1-40) aggregation by a tandem Abeta(40-1-Gly8-1-40) peptide.

Authors:  Sourajit M Mustafi; Kanchan Garai; Scott L Crick; Berevan Baban; Carl Frieden
Journal:  Biochem Biophys Res Commun       Date:  2010-05-31       Impact factor: 3.575

7.  Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths.

Authors:  S W Snyder; U S Ladror; W S Wade; G T Wang; L W Barrett; E D Matayoshi; H J Huffaker; G A Krafft; T F Holzman
Journal:  Biophys J       Date:  1994-09       Impact factor: 4.033

8.  Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.

Authors:  Manfred Windisch; Birgit Hutter-Paier; Edward Rockenstein; Makoto Hashimoto; Margaret Mallory; Eliezer Masliah
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

9.  Neurocytopathic effects of beta-amyloid-stimulated monocytes: a potential mechanism for central nervous system damage in Alzheimer disease.

Authors:  J A London; D Biegel; J S Pachter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.